A clinic based, Phase IIa, randomised, double-blind, placebo-controlled, ascending dose, single centre study investigating the safety, tolerability, efficacy, and pharmacokinetics of VR040 in patients with established idiopathic Parkinson's Disease
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2016
At a glance
- Drugs Apomorphine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 07 Sep 2012 Planned end date changed from 2 May 2006 to 1 May 2007 as reported by ClinicalTrials.gov.